In murine cancer models, the gamma isoform of phosphoinositide 3-kinase (PI3Kγ), which is highly expressed in myeloid cells, can be targeted with a selective inhibitor that reprograms MDSCs and improves responses to antibodies targeting CTLA4, PD-1, or both (61). The gene discussed is CTLA4; the disease is cancer.